Floatz logo

(+)-VINCRISTINE

Iparomlimab and Tuvonralimab Injection

Nanfang Hospital, Southern Medical UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Iparomlimab and Tuvonralimab Injection cohort.

Asset / SponsorPhaseRating
Tuvonralimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2B
Iparomlimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2B
Irinotecan
Nanfang Hospital, Southern Medical University
Phase 2CCC
Regorafenib
JIANG LONGWEI
Early Phase 1C

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →